Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Compugen Stock Got Slammed Today

TheMotleyFool

0 0

Compugen (NASDAQ: CGEN) stock didn't begin this week in a healthy way. The clinical-stage drug company's shares fell by just over 7% following a price target cut from an analyst tracking the company.

Prognosticator Mark Breidenbach of Oppenheimer has trimmed said target by just over 10% to $17 per share from the previous $19. Yet he is maintaining his outperform -- i.e., buy -- rating on the shares.

Image source: Getty Images.

Source Fool.com

Like: 0

CGEN

Share